Severity of liver disease among chronic hepatitis C patients: An observational study of 4594 patients in five European countries

Background and Aim Assessment of the severity of liver disease following infection with hepatitis C virus (HCV) is important in treatment selection and prognosis. As invasive liver biopsy procedures are regarded as the reference method to assess the stage of fibrosis, it is important to identify pat...

Full description

Saved in:
Bibliographic Details
Published inJournal of gastroenterology and hepatology Vol. 30; no. 2; pp. 364 - 371
Main Authors Marcellin, Patrick, Grotzinger, Kelly, Theodore, Dickens, Demuth, Dirk, Manns, Michael, Bañares Cañizares, Rafael, Pike, James, Forssen, Ulla M
Format Journal Article
LanguageEnglish
Published Australia Blackwell Publishing Ltd 01.02.2015
Subjects
Online AccessGet full text

Cover

Loading…
More Information
Summary:Background and Aim Assessment of the severity of liver disease following infection with hepatitis C virus (HCV) is important in treatment selection and prognosis. As invasive liver biopsy procedures are regarded as the reference method to assess the stage of fibrosis, it is important to identify patient characteristics that are predictive of liver fibrosis severity. The aim of the study was to describe the distribution of liver severity scores, clinical characteristics, and physicians' assessment of fibrosis among HCV patients in five European countries. Methods This cross‐sectional study retrospectively reviewed the medical records of patients who were chronically infected with HCV in 2006. Patients managed for HCV at any of 60 sites in France, Germany, Italy, Spain, and the UK were included. Data collected included patient demographics and clinical characteristics. A combination of univariate and multivariate regression analyses were used to identify predictors of fibrosis severity and factors associated with undergoing biopsy. Results Four thousand five hundred and ninety‐four chronically infected HCV patients were included in this analysis. Management approaches differed between countries, with variations in biopsy use (59.3–18.4%) and preferred fibrosis scoring systems. Where histology results were available, 43.4%, 23.8%, and 32.9% had mild, moderate, and severe fibrosis, respectively. Factors associated with undergoing a biopsy included male gender and co‐infection with hepatitis B virus. Chronic alcoholism, a lower first platelet count, and older age were predictors of increased liver fibrosis severity. Conclusions These data suggest that there are major differences in how specialists manage their HCV patients across five major European countries.
Bibliography:ArticleID:JGH12698
ark:/67375/WNG-1ZPW91H2-X
GlaxoSmithKline (GSK)
istex:FBB73FE99C8CB7577B5C7157557227E5C3927BEE
ObjectType-Article-1
SourceType-Scholarly Journals-1
ObjectType-Feature-2
content type line 23
ISSN:0815-9319
1440-1746
DOI:10.1111/jgh.12698